NADH
Research reviewed: 2024-2025
NADH (Reduced Nicotinamide Adenine Dinucleotide) is a dietary supplement with 14 published peer-reviewed studies involving 412 participants, researched for Parkinson's Disease, Chronic Fatigue, Cognitive Support and 2 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Parkinson's Disease
ModerateChronic Fatigue
ModerateCognitive Support
ModerateHeart Health
ModerateCognitive Function
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Parkinson's Disease
To assess NADH (IV and oral) in Parkinson's disease patients
Study Type
Open-label clinical trial
Purpose
To assess NADH (IV and oral) in Parkinson's disease patients
Dose
IV and oral NADH formulations
Participants
885 Parkinson's disease patients
Duration
Up to 5 years follow-up
Results
About 60% of Parkinson's patients showed clinical improvement with NADH treatment. Both IV and oral forms effective. PMID: 8101414
How They Measured It
Parkinson's disability scale, motor function, dopamine metabolites
To evaluate NADH coenzyme for Parkinson's disease disability improvement
Study Type
Open-label pilot study
Purpose
To evaluate NADH coenzyme for Parkinson's disease disability improvement
Dose
IV NADH 12.5-25 mg
Participants
34 Parkinson's disease patients
Duration
Acute infusion
Results
IV NADH improved disability scores in Parkinson's disease patients. Proposed mechanism: NADH stimulates dopamine synthesis via tyrosine hydroxylase activation. PMID: 2597315
How They Measured It
Parkinsonian disability scale, unified PD rating scale
To assess whether NADH is effective in Parkinson's disease treatment
Study Type
Review
Purpose
To assess whether NADH is effective in Parkinson's disease treatment
Dose
Various
Participants
N/A
Duration
N/A
Results
NADH indirectly boosts dopamine production by supporting tyrosine hydroxylase activity. Clinical evidence shows benefits in some patients, particularly those with preserved dopaminergic neurons. PMID: 9805207
How They Measured It
Evidence-based review of clinical trials
Chronic Fatigue
To assess NADH on chronic fatigue syndrome (CFS) symptoms and energy
Study Type
Randomised double-blind placebo-controlled
Purpose
To assess NADH on chronic fatigue syndrome (CFS) symptoms and energy
Dose
10 mg/day stabilised oral NADH
Participants
31 CFS patients
Duration
12 weeks
Results
26% of patients responded to NADH vs 8% placebo. Responders showed significant improvements in fatigue, cognitive performance, and quality of life. PMID: 10706219
How They Measured It
Fatigue scores, cognitive function, energy levels
To evaluate NADH depletion in CFS patients and therapeutic implications
Study Type
Clinical study
Purpose
To evaluate NADH depletion in CFS patients and therapeutic implications
Dose
10-20 mg/day
Participants
41 CFS patients
Duration
8 weeks
Results
NADH levels were significantly depleted in CFS patients. Supplementation restored levels and improved fatigue scores in majority of patients. PMID: 20447621
How They Measured It
NADH levels, fatigue scores, response to supplementation
To evaluate safety and effectiveness of NAD and NADH supplementation in various clinical conditions
Study Type
Systematic review
Purpose
To evaluate safety and effectiveness of NAD and NADH supplementation in various clinical conditions
Dose
Various
Participants
Multiple conditions including CFS, PD, ageing, diabetes
Duration
Various
Results
NADH supplementation was well tolerated. Evidence for decreased anxiety, improved insulin sensitivity, and reduced fatigue across multiple clinical conditions. PMID: 37971292
How They Measured It
Systematic review of RCTs and clinical studies
Cognitive Support
To evaluate NADH on cognitive function in healthy older adults
Study Type
Randomised controlled trial
Purpose
To evaluate NADH on cognitive function in healthy older adults
Dose
10 mg/day oral NADH
Participants
36 healthy older adults
Duration
8 weeks
Results
NADH supplementation significantly improved cognitive performance scores and subjective energy levels vs placebo in healthy older adults.
How They Measured It
Cognitive function battery, energy, quality of life
To assess NADH on stress test performance and heart rate in healthy volunteers
Study Type
Randomised controlled trial
Purpose
To assess NADH on stress test performance and heart rate in healthy volunteers
Dose
20 mg/day NADH
Participants
40 healthy volunteers
Duration
4 weeks
Results
NADH supplementation significantly decreased maximum heart rate during stress test and improved recovery, indicating improved cardiovascular efficiency.
How They Measured It
Heart rate at maximal stress test, VO2max, recovery markers
To investigate NADH neuroprotection in Alzheimer's disease model
Study Type
Animal study
Purpose
To investigate NADH neuroprotection in Alzheimer's disease model
Dose
Oral NADH supplementation
Participants
Transgenic Alzheimer's mice
Duration
6 months
Results
NADH supplementation reduced amyloid-beta accumulation and improved cognitive performance by preserving mitochondrial function in Alzheimer's mouse model.
How They Measured It
Amyloid-beta, cognitive tests, mitochondrial function
Heart Health
Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial.
Study Type
RCT
Purpose
Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial.
Dose
See study
Participants
Not specified
Duration
26 weeks
Results
significantly improved arterial stiffness, as indicated by CAVI, and likely suppressed renal functional decline in patients with WS.
How They Measured It
PubMed PMID: 40459998. Aging Cell
The effect of a systematic multi-dimensional assessment in severe uncontrolled asthma: a literature review and protocol for an investigator-initiated,
Study Type
RCT
Purpose
The effect of a systematic multi-dimensional assessment in severe uncontrolled asthma: a literature review and protocol for an investigator-initiated,
Dose
See study
Participants
Not specified
Duration
6 weeks
Results
Study results available at linked source.
How They Measured It
PubMed PMID: 40382637. BMC Pulm Med
Nicotinamide modulates gut microbial metabolic potential and accelerates recovery in mild-to-moderate COVID-19.
Study Type
RCT
Purpose
Nicotinamide modulates gut microbial metabolic potential and accelerates recovery in mild-to-moderate COVID-19.
Dose
See study
Participants
Not specified
Duration
4 weeks
Results
Study results available at linked source.
How They Measured It
PubMed PMID: 40355744. Nat Metab
Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trial
Study Type
Meta-Analysis
Purpose
Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trial
Dose
See study
Participants
Not specified
Duration
12 weeks
Results
significantly positive impacts on glucose control and lipid profile.
How They Measured It
PubMed PMID: 39531138. Curr Diab Rep
Cognitive Function
Effects of Nicotinamide Mononucleotide Supplementation on Muscle and Liver Functions Among the Middle-aged and Elderly: A Systematic Review and Meta-a
Study Type
Meta-Analysis
Purpose
Effects of Nicotinamide Mononucleotide Supplementation on Muscle and Liver Functions Among the Middle-aged and Elderly: A Systematic Review and Meta-a
Dose
See study
Participants
412 participants
Duration
Not specified
Results
CONCLUSION: NMN has positive efficacy in enhancing muscle function, reducing insulin resistance and lowering aminotransferase levels in middle-aged and elderly individuals.
How They Measured It
PubMed PMID: 39185644. Curr Pharm Biotechnol
Frequently Asked Questions
Common questions about NADH research
There are currently 14 peer-reviewed studies on NADH (Reduced Nicotinamide Adenine Dinucleotide), involving 412 total participants. Research covers Chronic fatigue, Parkinson's disease, Cognitive support. The overall evidence strength is rated as Strong.
The evidence is currently rated as "Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (11 human studies, 1 animal study), and reported outcomes.
NADH has been researched for: Chronic fatigue, Parkinson's disease, Cognitive support. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 11 out of 14 studies are human trials. The remaining 1 is an animal study. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
